See more : Ganesha Ecosphere Limited (GANECOS.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Savara Inc. (SVRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Savara Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Techno Alpha Co., Ltd. (3089.T) Income Statement Analysis – Financial Results
- PGS ASA (PGEJF) Income Statement Analysis – Financial Results
- Zosano Pharma Corporation (ZSAN) Income Statement Analysis – Financial Results
- PMV Consumer Acquisition Corp. (PMVC-WT) Income Statement Analysis – Financial Results
- Neturen Co., Ltd. (5976.T) Income Statement Analysis – Financial Results
Savara Inc. (SVRA)
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 257.00K | 0.00 | 0.00 | 0.00 | 400.00K | 54.00 | 1.55K | 0.00 | 0.00 | 0.00 | 488.96K | 300.00K | 500.00K | 500.00K | 0.00 | 496.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 44.26M | 167.00K | 367.00K | 35.04K | 1.01M | 526.00K | 363.00K | 0.00 | 146.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -44.26M | -167.00K | -367.00K | 221.96K | -1.01M | -526.00K | -363.00K | 400.00K | -145.95K | 1.55K | 0.00 | 0.00 | 0.00 | 488.96K | 300.00K | 500.00K | 500.00K | 0.00 | 496.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 86.37% | 0.00% | 0.00% | 0.00% | 100.00% | -270,270.37% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 44.26M | 27.88M | 28.99M | 35.04M | 38.78M | 37.17M | 18.51M | 8.18M | 28.26M | 19.44M | 12.90M | 8.09M | 5.76M | 3.69M | 6.51M | 17.92M | 15.93M | 12.00M | 8.68M | 2.74M | 749.00K | 282.97K | 946.42K | 1.02M |
| General & Administrative | 15.67M | 10.93M | 12.35M | 14.26M | 13.08M | 10.65M | 11.08M | 2.82M | 10.96M | 9.49M | 8.52M | 7.52M | 7.60M | 5.32M | 5.00M | 9.72M | 8.68M | 7.24M | 4.90M | 4.02M | 1.59M | 1.39M | 2.04M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -410.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.67M | 10.93M | 12.35M | 14.26M | 13.08M | 10.65M | 11.08M | 2.82M | 10.96M | 9.49M | 8.52M | 7.52M | 7.19M | 5.32M | 5.00M | 9.72M | 8.68M | 7.24M | 4.90M | 4.02M | 1.59M | 1.39M | 2.04M | 793.97K |
| Other Expenses | -44.19M | -765.00K | -708.00K | -638.00K | 311.00K | 526.00K | 363.00K | -43.00K | 4.00K | 508.00K | -1.35K | -5.05K | 37.57K | 19.82K | 79.73K | 168.04K | 197.78K | 176.69K | 115.55K | 41.31K | 8.97K | 428.11K | 7.67M | 0.00 |
| Operating Expenses | 15.75M | 38.04M | 40.63M | 48.66M | 52.17M | 48.35M | 29.96M | 11.35M | 39.37M | 29.01M | 21.46M | 15.70M | 13.40M | 9.03M | 11.59M | 27.81M | 24.81M | 19.41M | 13.70M | 6.80M | 2.34M | 2.10M | 10.66M | 3.72M |
| Cost & Expenses | 60.01M | 38.04M | 40.63M | 48.66M | 52.17M | 48.35M | 29.96M | 11.35M | 39.37M | 29.01M | 21.46M | 15.70M | 13.40M | 9.03M | 11.59M | 27.81M | 24.81M | 19.41M | 13.70M | 6.80M | 2.34M | 2.10M | 10.66M | 3.72M |
| Interest Income | 4.44M | 88.00 | 2.28K | 1.48K | 0.00 | 0.00 | 0.00 | 122.00K | 130.00K | 69.00K | 60.27K | 73.56K | 76.59K | 92.87K | 7.16K | 549.96K | 2.17M | 1.16M | 496.06K | 103.04K | 9.27K | 1.27K | 31.69K | 40.92K |
| Interest Expense | 0.00 | 88.00K | 2.28M | 1.48M | 70.00K | 11.00K | 1.16M | 468.00K | 603.00K | 0.00 | 0.00 | 0.00 | 11.01K | 1.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.39K | 1.39K | 53.70K | 12.02K | 23.50K |
| Depreciation & Amortization | 175.00K | 167.00K | 367.00K | 693.00K | 1.01M | 526.00K | 363.00K | 346.00K | 146.00K | 85.00K | 39.52K | 90.05K | 38.00K | 19.82K | 79.73K | 168.04K | 197.78K | 176.69K | 115.55K | 41.31K | 8.97K | 428.11K | 7.67M | 1.91M |
| EBITDA | -59.13M | -37.90M | -40.37M | -47.44M | -77.09M | -69.50M | -31.91M | -10.48M | -39.09M | -28.62M | -21.44M | -15.47M | -13.22M | -8.43M | -11.21M | -27.14M | -24.11M | -29.16M | -13.09M | -6.66M | -2.32M | -1.72M | 2.72M | -1.81M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -18,565.76% | 0.00% | 0.00% | 0.00% | -2,650.50% | -72,642,592.59% | -1,850,904.39% | 0.00% | 0.00% | 0.00% | -1,741.95% | -3,719.81% | -5,318.37% | -4,822.65% | 0.00% | -303.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -60.01M | -38.84M | -41.48M | -49.30M | -79.03M | -70.05M | -29.96M | -10.95M | -39.37M | -29.28M | -21.54M | -15.63M | -13.40M | -8.54M | -11.29M | -27.31M | -24.31M | -29.84M | -13.20M | -6.80M | -2.34M | -2.10M | -10.66M | -3.72M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -19,182.88% | 0.00% | 0.00% | 0.00% | -2,737.00% | -72,912,962.96% | -1,891,408.27% | 0.00% | 0.00% | 0.00% | -1,746.51% | -3,761.90% | -5,461.97% | -4,862.21% | 0.00% | -2,661.58% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.31M | 689.00K | -1.54M | -315.00K | 852.00K | 18.00K | -3.48M | -332.00K | -469.00K | 577.00K | 58.92K | 68.51K | -273.93K | 88.78K | -39.37K | 662.34K | 2.17M | 504.69K | -11.58M | 103.04K | 11.49K | 45.79K | -5.70M | 0.00 |
| Income Before Tax | -54.70M | -38.15M | -43.01M | -49.62M | -78.17M | -70.03M | -33.43M | -11.28M | -39.84M | -28.70M | -21.48M | -15.56M | -13.26M | -8.45M | -11.33M | -26.65M | -22.14M | 29.33M | -24.78M | -2.33M | -2.33M | -2.05M | -16.36M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -19,305.45% | 0.00% | 0.00% | 0.00% | -2,820.00% | -73,781,481.48% | -1,854,134.37% | 0.00% | 0.00% | 0.00% | -1,728.35% | -3,775.02% | -5,329.50% | -4,428.41% | 0.00% | -4,995.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 796.00K | 2.28M | 1.48M | 26.85M | -8.51M | -3.63M | -357.00K | 473.00K | -306.00K | -1.35K | -5.05K | -65.62K | -88.78K | 39.37K | 0.00 | 0.00 | 9.92M | 11.58M | 4.37M | -11.49K | 6.63K | 5.68M | -17.43K |
| Net Income | -54.70M | -38.95M | -45.30M | -51.10M | -105.03M | -61.52M | -29.80M | -10.92M | -39.84M | -28.70M | -21.48M | -15.56M | -13.26M | -8.45M | -11.33M | -26.65M | -22.14M | -29.33M | -24.78M | -6.70M | -2.33M | -2.11M | -16.34M | -3.70M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -19,882.10% | 0.00% | 0.00% | 0.00% | -2,730.75% | -73,781,481.48% | -1,854,134.37% | 0.00% | 0.00% | 0.00% | -1,728.35% | -3,775.02% | -5,329.50% | -4,428.41% | 0.00% | -4,995.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.33 | -0.25 | -0.34 | -0.86 | -2.62 | -1.85 | -1.70 | -3.27 | -17.19 | -16.41 | -19.63 | -22.86 | -32.94 | -44.88 | -169.85 | -516.69 | -430.96 | -693.77 | -724.89 | -231.21 | -120.54 | -235.41 | -1.96K | -769.94 |
| EPS Diluted | -0.33 | -0.25 | -0.34 | -0.86 | -2.62 | -1.85 | -1.70 | -3.27 | -17.19 | -16.41 | -19.63 | -22.86 | -32.94 | -44.88 | -169.85 | -516.69 | -430.96 | -693.77 | -724.89 | -231.21 | -120.54 | -235.41 | -1.96K | -769.94 |
| Weighted Avg Shares Out | 165.20M | 152.77M | 133.92M | 59.31M | 40.03M | 33.30M | 17.52M | 3.35M | 2.32M | 1.75M | 1.09M | 680.60K | 402.51K | 188.30K | 66.68K | 51.57K | 51.38K | 42.28K | 34.19K | 28.98K | 19.35K | 8.95K | 8.34K | 4.81K |
| Weighted Avg Shares Out (Dil) | 165.20M | 152.77M | 133.92M | 59.31M | 40.03M | 33.30M | 17.52M | 3.35M | 2.32M | 1.75M | 1.09M | 680.60K | 402.51K | 188.30K | 66.68K | 51.57K | 51.38K | 42.28K | 34.19K | 28.98K | 19.35K | 8.95K | 8.34K | 4.81K |
Savara to Present at the Jefferies Healthcare Conference
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2023 at 10:30 am...
Why Shares of Savara Jumped on Tuesday
Savara is a clinical-stage pharmaceutical company with no revenue. The company expects a top-line readout on molgramostim in the second quarter of 2024.
Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023 at 1:20pm ET. A live...
Why Shares of Savara Soared This Week
The clinical-stage biopharmaceutical company focuses on therapies to treat rare respiratory diseases.
Savara to Present at H.C. Wainwright 24th Annual Global Investment Conference
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Matt Pauls, Chair and CEO, Savara will present at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14,...
3 Top Breakout Stocks to Add to Your Portfolio Now
Savara (SVRA), LGL Group (LGL) and Harte Hanks (HHS) have been selected as the breakout stocks for today.
Savara to Present at Jefferies Healthcare Conference
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Jefferies Healthcare Conference on June 8, 2022 at 1:00 pm ET in New York...
After Golden Cross, Savara Inc. (SVRA)'s Technical Outlook is Bright
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Savara to Present at Oppenheimer's 32nd Annual Healthcare Conference
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at Oppenheimer's 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 pm ET. A live...
Savara to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright BIOCONNECT Virtual Conference being held January 10-13, 2022. A webcast of the...
Source: https://incomestatements.info
Category: Stock Reports